TapewireFind a company

person · Reporting owner

Henderson Jeffrey William

Disclosed activity across 4 companies

Tapewire entity
14817
SEC CIK
0001324015

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BECTON DICKINSON & COBDX · Entity 2498DirectorJanuary 27, 2026January 29, 2026
HALOZYME THERAPEUTICS, INC.HALO · Entity 793DirectorMay 05, 2026May 07, 2026
KYNTRA BIO, INC.FGEN · Entity 7431DirectorSeptember 01, 2023September 07, 2023
QUALCOMM INC/DEQCOM · Entity 2852DirectorMarch 17, 2026March 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BECTON DICKINSON & CO

Report date January 27, 2026 · Filed January 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,143 Reported balance After 2026-01-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-01-27 · Grant · Acquired 1,098 · Balance 9,143

F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2: Includes units acquired through dividend investment since the last report filed by the reporting person.

Common StockSEC Table I · non-derivativeIndirectBy wife15 Reported balance Holding disclosure · report date 2026-01-27 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 15

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2: Includes units acquired through dividend investment since the last report filed by the reporting person.

HALOZYME THERAPEUTICS, INC.

Report date May 05, 2026 · Filed May 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect36,572 Reported balance After 2026-05-05 transaction · row 1
1 source row

Row 1 · 2026-05-05 · Grant · Acquired 3,796 · Balance 36,572

F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $65.87 · Expires 2036-05-05Direct6,040 Reported balance After 2026-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-05 · Grant · Acquired 6,040 · Balance 6,040

F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

KYNTRA BIO, INC.

Report date September 01, 2023 · Filed September 07, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect28,866 Reported balance After 2023-09-01 transaction · row 1
1 source row

Row 1 · 2023-09-01 · Sale · Disposed 2,000 · Balance 28,866

F1: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023.

F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.970 to $1.075. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023.

F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.970 to $1.075. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

QUALCOMM INC/DE

Report date March 17, 2026 · Filed March 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,598.6901 Reported balance After 2026-03-17 transaction · row 1
1 source row

Row 1 · 2026-03-17 · Grant · Acquired 2,563 · Balance 14,598.6901

F1: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2026 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 17, 2029 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2026 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 17, 2029 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 05, 2026 Filed May 7, 2026 23:02 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 6,040 $0.00 Strike: $65.87 $0.00
Disclosure

SEC source: 0001159036-26-000061 · wk-form4_1778194968.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,040

Underlying: Common Stock · 6,040 shares

Expires 2036-05-05

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
May 05, 2026 Filed May 7, 2026 23:02 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 3,796 $0.00 $0.00
Disclosure

SEC source: 0001159036-26-000061 · wk-form4_1778194968.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,572

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 22:07 UTC QUALCOMM INC/DE QCOM · Entity 2852 GrantCommon Stock 2,563 $0.00 $0.00
Disclosure

SEC source: 0000804328-26-000038 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,598.6901

F1 · shares: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2026 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 17, 2029 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date.

Read SEC document
March 08, 2026 Filed Mar 9, 2026 20:49 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionDeferred Stock Unit · Derivative 2,355.1987 $0.00 $0.00
Disclosure

SEC source: 0000804328-26-000025 · edgardoc.xml · derivative · entry 3

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,683.1728

Underlying: Common Stock · 2,355.1987 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document
March 08, 2026 Filed Mar 9, 2026 20:49 UTC QUALCOMM INC/DE QCOM · Entity 2852 Disposition to issuerCommon Stock 759 $135.69 $102,988.71
Disclosure

SEC source: 0000804328-26-000025 · edgardoc.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,035.6901

Read SEC document
March 08, 2026 Filed Mar 9, 2026 20:49 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionCommon Stock 2,355 $0.00 $0.00
Disclosure

SEC source: 0000804328-26-000025 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,794.6901

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 8, 2023.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:58 UTC BECTON DICKINSON & CO BDX · Entity 2498 GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004019 · wk-form4_1769698710.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,143

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
May 01, 2025 Filed May 2, 2025 20:06 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 5,750 $0.00 Strike: $60.03 $0.00
Disclosure

SEC source: 0001415889-25-011771 · form4-05022025_080526.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,750

Underlying: Common Stock · 5,750 shares

Expires 2035-05-01

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
May 01, 2025 Filed May 2, 2025 20:06 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 4,165 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-011771 · form4-05022025_080526.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,776

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
April 28, 2025 Filed Apr 28, 2025 22:04 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 200 $61.00 $12,199.00
Disclosure

SEC source: 0001415889-25-011432 · form4-04282025_100414.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,611

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $60.97 to $61.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 28, 2025 Filed Apr 28, 2025 22:04 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 4,297 $60.34 $259,268.09
Disclosure

SEC source: 0001415889-25-011432 · form4-04282025_100414.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,811

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $59.93 to $60.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 01, 2025 Filed Apr 1, 2025 22:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 503 $64.05 $32,217.15
Disclosure

SEC source: 0001415889-25-009440 · form4-04012025_100413.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,108

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

Read SEC document
March 18, 2025 Filed Mar 20, 2025 20:19 UTC QUALCOMM INC/DE QCOM · Entity 2852 GrantCommon Stock 2,097 $0.00 $0.00
Disclosure

SEC source: 0001888316-25-000025 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,406

F1 · shares: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2025 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 18, 2028 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date.

Read SEC document
March 09, 2025 Filed Mar 10, 2025 20:30 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionDeferred Stock Unit · Derivative 1,901.0354 $0.00 $0.00
Disclosure

SEC source: 0001888316-25-000015 · edgardoc.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,938.3647

Underlying: Common Stock · 1,901.0354 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document
March 09, 2025 Filed Mar 10, 2025 20:30 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionCommon Stock 1,901 $0.00 $0.00
Disclosure

SEC source: 0001888316-25-000015 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,309

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 9, 2022.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 01:46 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 3,205 $59.12 $189,466.78
Disclosure

SEC source: 0001415889-25-006323 · form4-03042025_010322.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,611

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.80 to $59.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 01:46 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 1,795 $57.93 $103,991.53
Disclosure

SEC source: 0001415889-25-006323 · form4-03042025_010322.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,816

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.73 to $58.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 22:03 UTC BECTON DICKINSON & CO BDX · Entity 2498 PurchaseCommon Stock 1,500 $233.62 $350,430.00
Disclosure

SEC source: 0001062993-25-001977 · form4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,015

Read SEC document
February 03, 2025 Filed Feb 4, 2025 23:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 3,900 $56.41 $219,979.50
Disclosure

SEC source: 0001415889-25-003006 · form4-02042025_110227.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,611

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.22 to $56.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 23:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 1,100 $55.94 $61,537.30
Disclosure

SEC source: 0001415889-25-003006 · form4-02042025_110227.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,511

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.22 to $56.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 28, 2025 Filed Jan 30, 2025 21:00 UTC BECTON DICKINSON & CO BDX · Entity 2498 GrantCommon Stock 930 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-001300 · form4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,515

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 21:14 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $50.01 $500,060.00
Disclosure

SEC source: 0001415889-25-000995 · form4-01072025_090159.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,611

F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 25, 2024 Filed Apr 29, 2024 21:56 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 8,804 $0.00 Strike: $38.46 $0.00
Disclosure

SEC source: 0001415889-24-011685 · form4-04292024_090447.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,804

Underlying: Common Stock · 8,804 shares

Expires 2034-04-25

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
April 25, 2024 Filed Apr 29, 2024 21:56 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 6,501 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-011685 · form4-04292024_090447.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,611

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
March 10, 2024 Filed Mar 11, 2024 21:09 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionDeferred Stock Unit · Derivative 2,056.6383 $0.00 $0.00
Disclosure

SEC source: 0001888316-24-000029 · edgardoc.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,726.0743

Underlying: Common Stock · 2,056.6383 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document
March 10, 2024 Filed Mar 11, 2024 21:09 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionCommon Stock 2,056 $0.00 $0.00
Disclosure

SEC source: 0001888316-24-000029 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 10, 2021.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:44 UTC QUALCOMM INC/DE QCOM · Entity 2852 GrantDeferred Stock Unit · Derivative 1,624 $0.00 $0.00
Disclosure

SEC source: 0001888316-24-000019 · edgardoc.xml · derivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,772.338

Underlying: Common Stock · 1,624 shares

Expires not disclosed

F1 · security: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2024 Director Compensation Plan.

F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 21:17 UTC BECTON DICKINSON & CO BDX · Entity 2498 GrantCommon Stock 900 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-001307 · form4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,568

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person.

Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:54 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 2,000 $1.03 $2,060.00
Disclosure

SEC source: 0001209191-23-048554 · doc4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,866

F1 · shares: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023.

F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.970 to $1.075. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
August 04, 2023 Filed Aug 8, 2023 23:10 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 2,000 $1.91 $3,820.00
Disclosure

SEC source: 0001209191-23-045087 · doc4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,866

F1 · shares: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023.

F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $1.865 to $1.925. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
July 11, 2023 Filed Jul 14, 2023 00:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 2,000 $2.69 $5,380.00
Disclosure

SEC source: 0001209191-23-042247 · doc4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,866

F1 · shares: Shares sold by the reporting person pursuant to a 10b5-1 trading plan.

F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $2.66 to $2.735. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
June 08, 2023 Filed Jun 9, 2023 23:52 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 4,994 $17.69 $88,343.86
Disclosure

SEC source: 0001209191-23-036074 · doc4.xml · nonDerivative · entry 3

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,866

F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.52 to $17.86. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
June 08, 2023 Filed Jun 9, 2023 23:52 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 2,006 $16.87 $33,841.22
Disclosure

SEC source: 0001209191-23-036074 · doc4.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,860

F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.52 to $17.51. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:52 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 12,666 $0.00 Strike: $17.13 $0.00
Disclosure

SEC source: 0001209191-23-036074 · doc4.xml · derivative · entry 4

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,666

Underlying: Common Stock · 12,666 shares

Expires 2033-06-06

F5 · derivative.exercise_date: Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:52 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 8,289 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-036074 · doc4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,866

F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Read SEC document
May 05, 2023 Filed May 9, 2023 22:19 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 11,371 $0.00 Strike: $31.00 $0.00
Disclosure

SEC source: 0001415889-23-007691 · form4-05092023_100551.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,371

Underlying: Common Stock · 11,371 shares

Expires 2033-05-05

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
May 05, 2023 Filed May 9, 2023 22:19 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 8,065 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-007691 · form4-05092023_100551.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,110

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
March 10, 2023 Filed Mar 13, 2023 22:47 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionDeferred Stock Unit · Derivative 3,316.6108 $0.00 $0.00
Disclosure

SEC source: 0001888316-23-000026 · edgardoc.xml · derivative · entry 3

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,004.412

Underlying: Common Stock · 3,316.6108 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document
March 10, 2023 Filed Mar 13, 2023 22:47 UTC QUALCOMM INC/DE QCOM · Entity 2852 Disposition to issuerCommon Stock 1,069 $115.19 $123,138.11
Disclosure

SEC source: 0001888316-23-000026 · edgardoc.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Read SEC document
March 10, 2023 Filed Mar 13, 2023 22:47 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionCommon Stock 3,316 $0.00 $0.00
Disclosure

SEC source: 0001888316-23-000026 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,421

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 10, 2020.

Read SEC document
March 08, 2023 Filed Mar 10, 2023 21:24 UTC QUALCOMM INC/DE QCOM · Entity 2852 GrantDeferred Stock Unit · Derivative 2,203 $0.00 $0.00
Disclosure

SEC source: 0001888316-23-000016 · edgardoc.xml · derivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,301.048

Underlying: Common Stock · 2,203 shares

Expires not disclosed

F1 · security: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2023 Director Compensation Plan.

F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document
March 01, 2023 Filed Mar 1, 2023 23:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $47.71 $477,100.00
Disclosure

SEC source: 0001415889-23-003703 · form4-03012023_110312.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,045

Read SEC document
February 28, 2023 Filed Mar 1, 2023 23:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $48.51 $485,100.00
Disclosure

SEC source: 0001415889-23-003703 · form4-03012023_110312.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,045

Read SEC document
February 23, 2023 Filed Feb 24, 2023 21:08 UTC QUALCOMM INC/DE QCOM · Entity 2852 SaleCommon Stock 2,500 $124.19 $310,468.50
Disclosure

SEC source: 0001888316-23-000008 · edgardoc.xml · nonDerivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,105

F2 · price: The sale prices for this transaction ranged from $124.08 to $124.36 The filer hereby agrees to provide, upon request, full information regarding the number of shares sold at each separate price.

Read SEC document
February 22, 2023 Filed Feb 24, 2023 21:08 UTC QUALCOMM INC/DE QCOM · Entity 2852 SaleCommon Stock 2,500 $124.05 $310,132.25
Disclosure

SEC source: 0001888316-23-000008 · edgardoc.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,605

F1 · price: The sale prices for this transaction ranged from $123.94 to $124.20 The filer hereby agrees to provide, upon request, full information regarding the number of shares sold at each separate price.

Read SEC document
January 24, 2023 Filed Jan 26, 2023 23:06 UTC BECTON DICKINSON & CO BDX · Entity 2498 GrantCommon Stock 848 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-001435 · form4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,653

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person.

Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:12 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 25,684 $0.00 Strike: $9.00 $0.00
Disclosure

SEC source: 0001209191-22-038613 · doc4.xml · derivative · entry 2

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,684

Underlying: Common Stock · 25,684 shares

Expires 2032-06-15

F2 · derivative.exercise_date: Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:12 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 15,777 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-038613 · doc4.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,577

F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Read SEC document
May 05, 2022 Filed May 7, 2022 00:06 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units 6,206 $0.00 $0.00
Disclosure

SEC source: 0001179110-22-002909 · edgar.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,045

F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
March 12, 2022 Filed Mar 15, 2022 20:08 UTC QUALCOMM INC/DE QCOM · Entity 2852 Exercise / conversionDeferred Stock Unit · Derivative 4,559.8255 $0.00 $0.00
Disclosure

SEC source: 0001888316-22-000022 · edgardoc.xml · derivative · entry 3

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,944.4914

Underlying: Common Stock · 4,559.8255 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

F2 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.